Lenalidomide (CC 5013)

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Also Known As:

CC 5013; Revlimid; 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H- isoindol-2-yl)-; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; CC-5013; CC5013; IMiD3 Cpd; Revimid

Networked: 3306 relevant articles (538 outcomes, 854 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Richardson, Paul G: 91 articles (10/2022 - 11/2002)
2.	Palumbo, Antonio: 73 articles (05/2020 - 07/2007)
3.	Dimopoulos, Meletios A: 70 articles (06/2022 - 03/2007)
4.	Anderson, Kenneth C: 66 articles (01/2022 - 11/2002)
5.	Moreau, Philippe: 66 articles (01/2022 - 05/2008)
6.	Rajkumar, S Vincent: 46 articles (01/2021 - 04/2005)
7.	Facon, Thierry: 42 articles (01/2022 - 11/2007)
8.	Lonial, Sagar: 41 articles (06/2022 - 10/2007)
9.	Sonneveld, Pieter: 41 articles (02/2022 - 04/2008)
10.	Fenaux, Pierre: 40 articles (01/2022 - 01/2006)

Related Diseases

1.	Multiple Myeloma 01/01/2020 - "One of the most common orally administered antimyeloma agents, lenalidomide, has significantly improved outcomes in multiple myeloma, including in older patients. " 05/01/2016 - "Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment." 01/01/2020 - "Lenalidomide is an immunomodulatory drug approved for maintenance treatment in newly diagnosed multiple myeloma, and it has been shown to improve progression-free survival (PFS) and, in several studies, overall survival. " 04/01/2019 - "Lenalidomide was effective in controlling both AITL and plasma cell myeloma." 11/01/2015 - "Lenalidomide is manageable and effective in multiple myeloma, particularly in elderly patients. "
2.	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 07/09/2015 - "Lenalidomide is a highly effective treatment for myelodysplastic syndrome (MDS) with deletion of chromosome 5q (del(5q)). " 07/01/2010 - "Efficacy of lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q)." 09/28/2022 - "The introduction of lenalidomide has significantly improved clinical outcomes in myelodysplastic syndrome (MDS) with isolated interstitial deletion of the long arm of chromosome 5 (del(5q)) (5q- syndrome). " 03/01/2010 - "The beneficial effect of lenalidomide in patients with lower risk myelodysplastic syndrome with del(5q) is associated with significant increases in the proportion of bone marrow erythroid precursor cells and in the frequency of clonogenic progenitor cells, a substantial improvement in the hematopoiesis-supporting potential of bone marrow stroma and significant alterations in the adhesion profile of bone marrow CD34(+) cells." 02/01/2006 - "Importantly, lenalidomide induces significant clinical responses even in patients with relapsed/refractory MM. Therefore, lenalidomide represents a new class of antitumour agents that is useful in the treatment of MM. Lenalidomide has received fast track designation from the FDA for the treatment of MM and myelodysplastic syndromes."
3.	Neoplasms (Cancer) 02/01/2007 - "The clinical results that we have seen so far, which demonstrate significant efficacy with a tolerable toxicity profile, provide a strong basis for the use of lenalidomide in other malignancies. " 09/01/2017 - "That study showed improved time to progression and overall survival and an increase in second primary malignancies for lenalidomide at a median follow-up of 34 months. " 01/01/2005 - "These data further support the use of lenalidomide as an orally administered drug for the effective treatment of angiogenesis-dependent conditions, including cancer, and suggest a potential mechanism of action." 11/01/2010 - "Lenalidomide is a novel immunomodulatory agent with a unique dual mechanism of action: its tumoricidal effect leads to direct tumor cell death, and its immunomodulatory effect keeps the tumor in remission. " 09/01/2020 - "Efficacy of lenalidomide in myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and an extreme platelet count."
4.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/01/2018 - "Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow." 01/01/2021 - "Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission." 10/01/2012 - "We conducted a phase II study to evaluate the safety and efficacy of lenalidomide in patients with relapsed/refractory acute myeloid leukemia (AML) and high-risk MDS with any chromosome 5 abnormality. " 01/01/2018 - "However, whether lenalidomide leads to a significant improvement in treatment response and overall survival (OS) in cases of acute myeloid leukemia (AML) remains controversial. " 01/01/2014 - "Patients who achieve transfusion independence and/or a cytogenetic response with lenalidomide have a decreased risk of progression to acute myeloid leukemia and an improved overall survival compared to non-responders. "
5.	Lymphoma (Lymphomas) 11/01/2019 - "We next evaluated the efficacy of lenalidomide and IFN-DC-based vaccination, either alone or in combination, in hu-PBL-NOD/SCID mice bearing established human lymphoma. " 01/01/2023 - "Several studies with lenalidomide have been found to have activity in the treatment of relapsed/refractory aggressive lymphomas. " 03/01/2020 - "The AUGMENT study: Lenalidomide in indolent lymphoma … balance the imbalance!" 10/24/2021 - "Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphomas." 01/01/2021 - "We consider the possible causes of this discordance involved AITL and EBV-positive DLBCL, and the possible mechanism of lenalidomide action in both T-cell and B-cell non-Hodgkin lymphomas. "

Related Drugs and Biologics

1.	Dexamethasone (Maxidex)
2.	Bortezomib (Velcade)
3.	Thalidomide (Thalomid)
4.	pomalidomide
5.	Immunomodulating Agents
6.	Rituximab (Mabthera)
7.	Proteasome Inhibitors
8.	carfilzomib
9.	daratumumab
10.	Cyclophosphamide (Cytoxan)

Related Therapies and Procedures

1.	Therapeutics
2.	Stem Cell Transplantation
3.	Drug Therapy (Chemotherapy)
4.	Transplantation
5.	Hematopoietic Stem Cell Transplantation